T-follicular helper cells in Env-immunized macaques

Env 免疫猕猴中的滤泡辅助 T 细胞

• 批准号: 8262539
• 负责人: C. David Pauza
• 金额: $ 23.03万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-01 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8262539
• 关键词: AIDS prevention; Affect; Affinity; Agonist; Animals; Antibodies; Antibody Formation; Antigens; B-Cell Development; B-Lymphocytes; BLR1 gene; Binding; Canarypox Vectors; Carbohydrates; Cell Differentiation process; Cell Maturation; Cell physiology; Cells; Cytoprotection; Defect; Development; Dose; Drops; Drug Formulations; Early Diagnosis; Evaluation Studies; Failure; Funding; Generations; Glycoproteins; Goals; HIV; HIV Infections; HIV vaccine; Helper-Inducer T-Lymphocyte; Human; Immune response; Immunity; Immunization; Integrin Binding; Integrins; Interleukin-12; Laboratories; Life; Macaca; Memory; Memory B-Lymphocyte; Modeling; Modification; Mus; Mutagenesis; Natural Killer Cells; Nature; Pathway interactions; Phenotype; Plasma; Polysaccharides; Poxviridae; Proteins; Public Health; Reaction; Recombinants; Risk; SIV Vaccines; Secondary Immunization; Signal Transduction; Specimen; Structure; Structure of germinal center of lymph node; T-Lymphocyte; TLR7 gene; Testing; Vaccines; Virus; Work; aluminum sulfate; arm; cytokine; env Gene Products; env Glycoproteins; improved; nonhuman primate; novel strategies; novel vaccines; pre-clinical; prevent; response; simian human immunodeficiency virus; vaccine development; vaccine efficacy; vaccine evaluation; volunteer

DESCRIPTION (provided by applicant): Protection from HIV was 60% at 12 months after immunizing low-risk volunteers with canarypox vCP1521 priming plus Envelope glycoprotein boosting (RV144 trial), but dropped to 29% after 42 months consistent with transient Env-specific antibodies (Kim, et al., 2010). Increasing the durability of protective immunity is a critcal objective for improving vaccines. Our goals are to identify defects in the immune response to antigen which block the normal pathways for generating B cell memory and fail to produce durable antibodies. We focus on CD4+/CXCR5+ T follicular helper cells (Tfh) which, together with antigen-specific B cells, normally initiate the germinal center reaction, promote affinity maturation of antibody and generate memory B cells. We postulate that Tfh are negatively impacted by Env and fail to support normal B cell development. Tfh have not been evaluated in HIV or SIV vaccine studies. They are poorly understood in nonhuman primates (NHP), where conditions for generating Tfh are unknown and functions of this subset have not been tested. Our efforts will relate Tfh to memory B cells in immunized NHP. Comparing animal groups that receive vector (canarypox), prime/boost (vCP1521 recombinant canarypox/Env glycoprotein), or Env alone, we ask whether Env has a negative effect on Tfh generation that is overcome by the vCP1521 priming immunization. Immunized macaques undergo repetitive, low-dose intrarectal virus challenge (as part of a funded preclinical vaccine study), allowing us to test whether Tfh and/or antibody-secreting memory B cells are correlates of protection that might be useful in human vaccine trials. Results from these studies will show whether transient antibody responses to vaccine reflect a fundamental defect in the pathway for memory B cell generation with Env antigens. Mitigation strategies might include modification of Env (changing protein or glycan structures), incorporation of cytokines, or vaccine formulations which add TLR7/8 agonists, all strategies to improve the Tfh response and memory B cell formation. There have been few efforts to determine mechanisms underlying the well-known transient antibody responses to Env glycoproteins. Our work concentrates on one aspect of antibody generation and tests its relationship to vaccine efficacy. PUBLIC HEALTH RELEVANCE: Current vaccines protect against HIV infection for around 1 year, but then begin to fail. Increasing the durability of protective immunity is key to obtaining vaccines which will impact public health. Our goals are to look for defects in the fundamental steps of generating long-term antibodies that have not been evaluated in previous animal or human vaccine studies. Results from this work may provide new approaches for early detection of protective antibody responses during vaccine trials and may guide the development of new vaccines with longer term protection against HIV.

描述（由申请人提供）：通过CanaryPox VCP1521 Priming Plus Prus Invelope糖蛋白增强（RV144试验）免疫低风险志愿者（RV144试验），在42个月后降至29％，在42个月后降至29％ （Kim等，2010）。提高保护性免疫的耐用性是改善疫苗的危险目标。我们的目标是确定对抗原的免疫反应中的缺陷，该反应阻止了生成B细胞记忆的正常途径，并且无法产生耐用的抗体。我们专注于CD4+/CXCR5+ T卵泡辅助细胞（TFH），该细胞与抗原特异性B细胞一起通常启动生发中心反应，促进抗体的亲和力成熟并产生记忆B细胞。我们假设TFH受到ENV的负面影响，并且无法支持正常的B细胞开发。 在HIV或SIV疫苗研究中尚未评估TFH。在非人类灵长类动物（NHP）中，它们对生成TFH的条件尚不清楚，并且该子集的功能尚未测试。我们的努力将将TFH与免疫NHP中的记忆B细胞有关。比较接收载体（CanaryPox），Prime/Boost（VCP1521重组canarypox/ENV糖蛋白）的动物群体，或者单独使用ENV，我们询问ENV对VCP1521的动物是否对TFH产生产生负面影响。免疫猕猴会经历重复的，低剂量的直肠病毒挑战（作为一项资助的临床前疫苗研究的一部分），使我们能够测试TFH和/或分泌抗体分泌记忆B细胞是否与可能在人类疫苗试验中有用的保护相关。 这些研究的结果将表明对疫苗的瞬时抗体反应是否反映了用ENV抗原产生记忆B细胞的途径中的基本缺陷。缓解策略可能包括修改ENV（变化的蛋白质或聚糖结构），掺入细胞因子或增加TLR7/8激动剂的疫苗制剂，这些策略是改善TFH响应和记忆B细胞形成的策略。几乎没有努力来确定众所周知的瞬时抗体对糖蛋白的反应的机制。我们的工作集中于抗体产生的一个方面，并测试了其与疫苗功效的关系。 公共卫生相关性：当前的疫苗可预防1年左右的艾滋病毒感染，但随后开始失败。提高保护性免疫的耐用性是获取会影响公共卫生的疫苗的关键。我们的目标是在产生长期抗体的基本步骤中寻找缺陷，而这些抗体尚未在先前的动物或人类疫苗研究中进行评估。这项工作的结果可能会为疫苗试验期间的保护性抗体反应提供新的方法，并可能指导开发具有长期保护艾滋病毒的新疫苗。